about
Antibodies inside of a cell can change its outside: Can intrabodies provide a new therapeutic paradigm?Applications of DNA integrating elements: Facing the bias bully"Freeze, Don't Move": How to Arrest a Suspect in Heart Failure - A Review on Available GRK2 InhibitorsNoncoding RNA in age-related cardiovascular diseasesGeneration of X-CGD cells for vector evaluation from healthy donor CD34(+) HSCs by shRNA-mediated knock down of gp91(phox).CD133-targeted gene transfer into long-term repopulating hematopoietic stem cellsAntibody-free magnetic cell sorting of genetically modified primary human CD4+ T cells by one-step streptavidin affinity purificationClinical applications of gene therapy for primary immunodeficiencies.Normalization and improvement of CNS deficits in mice with Hurler syndrome after long-term peripheral delivery of BBB-targeted iduronidase.Gene/cell therapy approaches for Immune Dysregulation Polyendocrinopathy Enteropathy X-linked syndrome.Receptor-Targeted Nipah Virus Glycoproteins Improve Cell-Type Selective Gene Delivery and Reveal a Preference for Membrane-Proximal Cell Attachment.Highly efficient in vitro and in vivo delivery of functional RNAs using new versatile MS2-chimeric retrovirus-like particles.Expression of a biotin acceptor peptide-containing protein with potential incorporation on the lentiviral envelope as a viral surface engineering platformLEDGF/p75 interacts with mRNA splicing factors and targets HIV-1 integration to highly spliced genes.Target delivery of small interfering RNAs with vitamin E-coupled nanoparticles for treating hepatitis CFunctional Restoration of gp91phox-Oxidase Activity by BAC Transgenesis and Gene Targeting in X-linked Chronic Granulomatous Disease iPSCs.Systemic epigenetic response to recombinant lentiviral vectors independent of proviral integrationGene therapy for primary immune deficiencies: a Canadian perspective.Synergistic effects of overexpression of BMP‑2 and TGF‑β3 on osteogenic differentiation of bone marrow mesenchymal stem cells.Lentiviral vectors for the treatment of primary immunodeficiencies.Manipulating mitochondrial genomes in the clinic: playing by different rules.Gene replacement therapy for genetic hepatocellular jaundice.CRISPR-Cas9: a new and promising player in gene therapy.Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.Targeting tumor suppressor genes for cancer therapy.Equine performance genes and the future of doping in horseracing.Shock Wave-Induced Damage and Poration in Eukaryotic Cell Membranes.Drug development challenges and strategies to address emerging and resistant fungal pathogens.Gene editing of DNAH11 restores normal cilia motility in primary ciliary dyskinesia.Receptor-targeted lentiviral vectors are exceptionally sensitive toward the biophysical properties of the displayed single-chain Fv.Anti-interleukin-6 therapy through application of a monogenic protein inhibitor via gene delivery.Non-viral nucleic acid delivery methods.Changing blue fluorescent protein to green fluorescent protein using chemical RNA editing as a novel strategy in genetic restoration.Intratracheal Gene Delivery of SERCA2a Ameliorates Chronic Post-Capillary Pulmonary Hypertension: A Large Animal Model.Off-target-free gene delivery by affinity-purified receptor-targeted viral vectors.Intracellular targeted co-delivery of shMDR1 and gefitinib with chitosan nanoparticles for overcoming multidrug resistance.CD105 is a surface marker for receptor-targeted gene transfer into human long-term repopulating hematopoietic stem cells.Peptides derived from evolutionarily conserved domains in Beclin1 and Beclin2 enhance the entry of lentiviral vectors into human cells.Assessment of transfection of AdCMV-EGFP to rat submandibular gland cells.Regulating the expression of therapeutic transgenes by controlled intake of dietary essential amino acids.
P2860
Q26738467-A4213F9D-0480-48BE-A9D0-8B0482F85467Q26781121-6C84B64B-707F-4302-AE29-DDF143110E90Q28078766-9C3213C6-2996-4187-9E55-990B4A7D91B0Q28081466-4F230913-5C62-488D-B16E-6E2E582BC3A3Q35184193-7AAA9BF7-29DA-4881-B0EA-4B2FA6FC0B4AQ35238704-30CA5632-8AAB-4D4B-8667-7CBB387D03EDQ35382218-6E228C6D-69BE-4E86-A827-5C769565DC51Q35539617-61D145FB-1A40-4D82-A44B-D444B5A81478Q35600316-D776CF89-87DA-44C8-9E50-3DBB129E3CB0Q35646681-197E88C8-8648-434F-BFE7-6486CCF5BD73Q36047074-18763383-36CE-4E03-8B43-15AE2A4AA2F9Q36185032-D7C1AB2A-7DD0-4405-876C-E2AABA7361C7Q36216709-AE90CC1F-BCD7-49D3-BEBE-5F808BDBE229Q36286785-0472C0F1-6454-4621-A5BF-30689EBDBD84Q36835758-897CA923-79F3-4B28-A483-3D13117482BCQ36951255-5DDC6BF1-B9DC-4877-86F6-E764DAA2FE28Q37084813-728D73E3-5048-40F9-8CEA-F3F218D4AC55Q37668317-6859A748-14D9-4BAC-8C85-4805752DF8DCQ37707669-05D57E68-780C-4131-8943-F845A4FD55BBQ38195200-EA647429-19CE-467A-8BD2-C35D740F861AQ38200226-AD04221A-956E-4D2F-A8A8-99BB200E1CF7Q38260248-F1312E56-E741-4444-A2F4-3620DF97E387Q38364993-480EF982-FD0D-469A-82F6-28A51E107DF5Q38435415-44BB87AB-280E-4748-83A9-02788B7A573AQ38601568-04D98006-EC89-4794-8776-4EE577BC2680Q38738678-6B072A2D-B5FC-417C-A538-6783D46A435CQ38750699-C990607B-FE64-4BE1-9788-879738921B5DQ38798805-ADCFD385-153D-499C-A616-7D4479164254Q38806595-27CF574A-3020-4039-9D92-B2CDD06301BBQ38906090-0DCD8F20-A3BE-4AE8-AB50-2A2E09265B5EQ38958166-D309DFFA-2AE2-4741-B5B2-C2CBB35FD519Q38980476-D22FCFAE-914A-4B1F-A4E5-E3D0605CF63DQ39000784-5310B63E-45B7-42F7-8B23-E2592BA2EB6FQ40776830-FCDCC925-02C2-42B6-AFD6-0F0753F9AB11Q41493938-0D028898-C518-4F79-B487-CF9BA29C4C07Q41836725-775FF1E4-4C8B-427B-A2A2-B330E5926C49Q41899254-0F90DB05-F512-49B8-999B-8C7330CFB5E5Q41934341-D4D1CE5A-F407-4455-867A-68F451697384Q42200872-245C70CC-B739-4B2B-BE2D-E5D85F37D04FQ42494301-8D8125E8-F260-4732-B203-664460126D13
P2860
description
2013 nî lūn-bûn
@nan
2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Gene therapy on the move
@ast
Gene therapy on the move
@en
Gene therapy on the move
@nl
type
label
Gene therapy on the move
@ast
Gene therapy on the move
@en
Gene therapy on the move
@nl
prefLabel
Gene therapy on the move
@ast
Gene therapy on the move
@en
Gene therapy on the move
@nl
P2093
P2860
P3181
P356
P1476
Gene therapy on the move
@en
P2093
Axel Schambach
Hildegard Büning
Manuel Grez
P2860
P304
P3181
P356
10.1002/EMMM.201202287
P407
P577
2013-11-01T00:00:00Z